Clinical trial NCT00144339: Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pulmonary Disease, Chronic Obstructive
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2005-09-05
Enrollment: 5993
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Eligibility criteria: Inclusion Criteria:

* Written informed consent.
* Male or female patients 40 years of age or older.
* Smoking history of at least 10 pack years.
* Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1\<70% of FVC and on stable respiratory medication.

Exclusion Criteria:

* Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.
* Myocardial infarction in past 6 months.
* Unstable or life threatening arrhythmia in past year.
* Hospitalization for NYHA heart failure class III or IV in past year.
* Active tuberculosis.
* Asthma.
* Pulmonary resection.
* Malignancy treated with radiation or chemotherapy in past 5 years.
* Respiratory infection in 4 weeks prior to screening.
* Known hypersensitivity to anticholinergic drugs or components.
* Known moderate to severe renal impairment.
* Known narrow angle glaucoma.
* Significant symptomatic BPH or bladder neck obstruction.
* Need for oxygen therapy \>12 hr/day.
* Use of oral corticosteroids at unstable doses or \>10 mg/day.

Primary outcomes:
measure: Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
measure: Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
Secondary outcomes:
measure: Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
measure: Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
measure: Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
measure: Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
measure: Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
measure: Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
timeFrame: From day 30 to 4 years
measure: Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score
timeFrame: From month 6 to 4 years
measure: Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
measure: Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
measure: Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
measure: Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
timeFrame: Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
measure: Time to First Exacerbation
timeFrame: From Day 1 to 4 years
measure: Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year
timeFrame: Day 1 to 4 years
measure: Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
timeFrame: Day 1 to 4 years
measure: Number of Exacerbation Days Per Patient Year
timeFrame: Day 1 to 4 years
measure: Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)
timeFrame: Day 1 to 4 years
measure: Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization
timeFrame: From Day 1 to 4 years
measure: Number of Exacerbation Leading to Hospitalization
timeFrame: From Day 1 to 4 years
measure: Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization
timeFrame: From Day 1 to 4 years
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
timeFrame: Month 1
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
timeFrame: Month 1
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
timeFrame: Month 6
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
timeFrame: Month 6
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
timeFrame: Month 12
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
timeFrame: Month 12
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
timeFrame: Month 18
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
timeFrame: Month 18
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
timeFrame: Month 24
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
timeFrame: Month 24
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
timeFrame: Month 30
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
timeFrame: Month 30
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
timeFrame: Month 36
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
timeFrame: Month 36
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
timeFrame: Month 42
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
timeFrame: Month 42
measure: Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
timeFrame: Month 48
measure: Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
timeFrame: Month 48
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1
timeFrame: Month 1
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1
timeFrame: Month 1
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6
timeFrame: Month 6
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6
timeFrame: Month 6
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12
timeFrame: Month 12
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12
timeFrame: Month 12
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18
timeFrame: Month 18
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18
timeFrame: Month 18
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24
timeFrame: Month 24
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24
timeFrame: Month 24
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30
timeFrame: Month 30
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30
timeFrame: Month 30
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36
timeFrame: Month 36
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36
timeFrame: Month 36
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42
timeFrame: Month 42
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42
timeFrame: Month 42
measure: Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48
timeFrame: Month 48
measure: Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48
timeFrame: Month 48
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1
timeFrame: Month 1
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1
timeFrame: Month 1
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6
timeFrame: Month 6
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6
timeFrame: Month 6
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12
timeFrame: Month 12
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12
timeFrame: Month 12
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18
timeFrame: Month 18
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18
timeFrame: Month 18
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24
timeFrame: Month 24
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24
timeFrame: Month 24
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30
timeFrame: Month 30
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30
timeFrame: Month 30
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36
timeFrame: Month 36
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36
timeFrame: Month 36
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42
timeFrame: Month 42
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42
timeFrame: Month 42
measure: Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48
timeFrame: Month 48
measure: Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48
timeFrame: Month 48
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6
timeFrame: Month 6
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12
timeFrame: Month 12
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18
timeFrame: Month 18
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24
timeFrame: Month 24
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30
timeFrame: Month 30
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36
timeFrame: Month 36
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42
timeFrame: Month 42
measure: Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48
timeFrame: Month 48
measure: Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
measure: Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)
timeFrame: Day 1 to day 1470
measure: Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
measure: Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)
timeFrame: Day 1 to day 1470
Other outcomes:
measure: Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Angina)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
measure: Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)
timeFrame: Day 1 to completion of double blinded treatment plus 30 days
Locations:
city: Anniston
country: United States
facility: 205.235.3779 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 205.235.3785 Boehringer Ingelheim Investigational Site
state: Alabama
city: Jasper
country: United States
facility: 205.235.3804 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 205.235.3795 Boehringer Ingelheim Investigational Site
state: Alabama
city: Phoenix
country: United States
facility: 205.235.3759 Boehringer Ingelheim Investigational Site
state: Arizona
city: Carmichael
country: United States
facility: 205.235.3770 Boehringer Ingelheim Investigational Site
state: California
city: Escondito
country: United States
facility: 205.235.3778 Boehringer Ingelheim Investigational Site
state: California
city: Lakewood
country: United States
facility: 205.235.3810 Boehringer Ingelheim Investigational Site
state: California
city: Long Beach
country: United States
facility: 205.235.3758 Boehringer Ingelheim Investigational Site
state: California
city: Long Beach
country: United States
facility: 205.235.3812 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 205.235.3773 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 205.235.3800 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 205.235.3802 Boehringer Ingelheim Investigational Site
state: California
city: Orange
country: United States
facility: 205.235.3786 Pulmonary and Critical Care Medicine
state: California
city: Palo Alto
country: United States
facility: 205.235.3811 Boehringer Ingelheim Investigational Site
state: California
city: Rancho Mirage
country: United States
facility: 205.235.3741 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 205.235.3717 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 205.235.3781 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 205.235.3784 Boehringer Ingelheim Investigational Site
state: California
city: Sepulveda
country: United States
facility: 205.235.3760 Boehringer Ingelheim Investigational Site
state: California
city: Stockton
country: United States
facility: 205.235.3711 Boehringer Ingelheim Investigational Site
state: California
city: Denver
country: United States
facility: 205.235.3764 Boehringer Ingelheim Investigational Site
state: Colorado
city: Wheat Ridge
country: United States
facility: 205.235.3783 Boehringer Ingelheim Investigational Site
state: Colorado
city: Hartford
country: United States
facility: 205.235.3727 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Hartford
country: United States
facility: 205.235.3808 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Norwalk
country: United States
facility: 205.235.3793 Boehringer Ingelheim Investigational Site
state: Connecticut
city: WEst Haven
country: United States
facility: 205.235.3815 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Bay Pines
country: United States
facility: 205.235.3706 Boehringer Ingelheim Investigational Site
state: Florida
city: Brandon
country: United States
facility: 205.235.3762 Boehringer Ingelheim Investigational Site
state: Florida
city: Largo
country: United States
facility: 205.235.3707 Boehringer Ingelheim Investigational Site
state: Florida
city: Melbourne
country: United States
facility: 205.235.3703 Boehringer Ingelheim Investigational Site
state: Florida
city: Panama City
country: United States
facility: 205.235.3775 Boehringer Ingelheim Investigational Site
state: Florida
city: Sarasota
country: United States
facility: 205.235.3743 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 205.235.3756 Boehringer Ingelheim Investigational Site
state: Florida
city: West Palm Beach
country: United States
facility: 205.235.3739 Boehringer Ingelheim Investigational Site
state: Florida
city: Atlanta
country: United States
facility: 205.235.3719 Boehringer Ingelheim Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: 205.235.3790 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 205.235.3716 Boehringer Ingelheim Investigational Site
state: Georgia
city: Stockbridge
country: United States
facility: 205.235.3794 Boehringer Ingelheim Investigational Site
state: Georgia
city: Coeur d'Alene
country: United States
facility: 205.235.3724 Boehringer Ingelheim Investigational Site
state: Idaho
city: Normal
country: United States
facility: 205.235.3713 Boehringer Ingelheim Investigational Site
state: Illinois
city: Indianapolis
country: United States
facility: 205.235.3768 Boehringer Ingelheim Investigational Site
state: Indiana
city: Dubuque
country: United States
facility: 205.235.3749 Boehringer Ingelheim Investigational Site
state: Iowa
city: Olathe
country: United States
facility: 205.235.3757 Boehringer Ingelheim Investigational Site
state: Kansas
city: Lexington
country: United States
facility: 205.235.3729 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Metairie
country: United States
facility: 205.235.3737 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Shreveport
country: United States
facility: 205.235.3788 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Bidderford
country: United States
facility: 205.235.3750 Boehringer Ingelheim Investigational Site
state: Maine
city: Baltimore
country: United States
facility: 205.235.3806 Boehringer Ingelheim Investigational Site
state: Maryland
city: Boston
country: United States
facility: 205.235.3721 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Springfield
country: United States
facility: 205.235.3726 354 Birnie Ave
state: Massachusetts
city: Ann Arbor
country: United States
facility: 205.235.3813 Boehringer Ingelheim Investigational Site
state: Michigan
city: Detroit
country: United States
facility: 205.235.3732 Boehringer Ingelheim Investigational Site
state: Michigan
city: Livonia
country: United States
facility: 205.235.3809 Boehringer Ingelheim Investigational Site
state: Michigan
city: Minneapolis
country: United States
facility: 205.235.3751 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 205.235.3754 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Rochester
country: United States
facility: 205.235.3789 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Chesterfield
country: United States
facility: 205.235.3734 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kansas City
country: United States
facility: 205.235.3814 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 205.235.3747 Boehringer Ingelheim Investigational Site
state: Missouri
city: Lebanon
country: United States
facility: 205.235.3763 Boehringer Ingelheim Investigational Site
state: New Hampshire
city: Cherry Hill
country: United States
facility: 205.235.3797 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Summit
country: United States
facility: 205.235.3799 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Albany
country: United States
facility: 205.235.3796 Boehringer Ingelheim Investigational Site
state: New York
city: Bayshore
country: United States
facility: 205.235.3807 Boehringer Ingelheim Investigational Site
state: New York
city: Bronx
country: United States
facility: 205.235.3816 Boehringer Ingelheim Investigational Site
state: New York
city: Larchmont
country: United States
facility: 205.235.3765 Boehringer Ingelheim Investigational Site
state: New York
city: Mineola
country: United States
facility: 205.235.3748 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 205.235.3818 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 205.235.3722 Boehringer Ingelheim Investigational Site
state: New York
city: Burlington
country: United States
facility: 205.235.3730 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Chapel Hill
country: United States
facility: 205.235.3731 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Durham
country: United States
facility: 205.235.3736 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Elizabath City
country: United States
facility: 205.235.3745 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston-Salem
country: United States
facility: 205.235.3712 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Cincinnati
country: United States
facility: 205.235.3723 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 205.235.3701 Boehringer Ingelheim Investigational Site
state: Ohio
city: Tulsa
country: United States
facility: 205.235.3791 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Portland
country: United States
facility: 205.235.3820 Boehringer Ingelheim Investigational Site
state: Oregon
city: Hershey
country: United States
facility: 205.235.3725 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 205.235.3817 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Providence
country: United States
facility: 205.235.3715 Boehringer Ingelheim Investigational Site
state: Rhode Island
city: El Paso
country: United States
facility: 205.235.3803 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 205.235.3742 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 205.235.3787 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 205.235.3704 Boehringer Ingelheim Investigational Site
state: Texas
city: Salt Lake City
country: United States
facility: 205.235.3752 Boehringer Ingelheim Investigational Site
state: Utah
city: Danville
country: United States
facility: 205.235.3744 Boehringer Ingelheim Investigational Site
state: Virginia
city: Fredericksburg
country: United States
facility: 205.235.3782 Boehringer Ingelheim Investigational Site
state: Virginia
city: Lynchburg
country: United States
facility: 205.235.3771 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 205.235.3738 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 205.235.3792 Boehringer Ingelheim Investigational Site
state: Virginia
city: Salem
country: United States
facility: 205.235.3761 Boehringer Ingelheim Investigational Site
state: Virginia
city: Spokane
country: United States
facility: 205.235.3718 Boehringer Ingelheim Investigational Site
state: Washington
city: La Crosse
country: United States
facility: 205.235.3780 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Buenos Aires
country: Argentina
facility: 205.235.101
city: Capital Federal
country: Argentina
facility: 205.235.101 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 205.235.103 Hospital Alemán
city: Capital Federal
country: Argentina
facility: 205.235.104 Hospital de Clinicas José de San Martín
city: Capital Federal
country: Argentina
facility: 205.235.105 Hospital General de Agudos José María Ramos Mejía
city: Capital Federal
country: Argentina
facility: 205.235.107 Policlínica Bancaria
city: Capital Federal
country: Argentina
facility: 205.235.108 Hospital General de Agudos Dr. Enrique Tornú
city: Capital Federal
country: Argentina
facility: 205.235.109 Hospital Muñiz
city: Parque Velez Sarlfield
country: Argentina
facility: 205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.
city: Rosario
country: Argentina
facility: 205.235.102 Instituto Cardiovascular de Rosario
city: Vicente López
country: Argentina
facility: 205.235.106 Hospital Cetrángolo
city: Bankstown
country: Australia
facility: 205.235.0205 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Concord
country: Australia
facility: 205.235.0202 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Westmead
country: Australia
facility: 205.235.0209 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Cairns
country: Australia
facility: 205.235.0204 Boehringer Ingelheim Investigational Site
state: Queensland
city: Redcliffe
country: Australia
facility: 205.235.0203 Boehringer Ingelheim Investigational Site
state: Queensland
city: Port Lincoln
country: Australia
facility: 205.235.0207 Boehringer Ingelheim Investigational Site
state: South Australia
city: Box Hill
country: Australia
facility: 205.235.0206 Boehringer Ingelheim Investigational Site
state: Victoria
city: Geelong
country: Australia
facility: 205.235.0201 Boehringer Ingelheim Investigational Site
state: Victoria
city: Graz
country: Austria
facility: 205.235.0303 Boehringer Ingelheim Investigational Site
city: Innsbruck
country: Austria
facility: 205.235.0305 Boehringer Ingelheim Investigational Site
city: Leoben
country: Austria
facility: 205.235.0304 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.235.0301 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.235.0302 Boehringer Ingelheim Investigational Site
city: Anderlecht
country: Belgium
facility: 205.235.0439 Boehringer Ingelheim Investigational Site
city: Baudour
country: Belgium
facility: 205.235.0429 Boehringer Ingelheim Investigational Site
city: Brugge
country: Belgium
facility: 205.235.0421 Boehringer Ingelheim Investigational Site
city: Brussel
country: Belgium
facility: 205.235.0424 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 205.235.0432 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 205.235.0434 Boehringer Ingelheim Investigational Site
city: Dendermonde
country: Belgium
facility: 205.235.0422 Boehringer Ingelheim Investigational Site
city: Edegem
country: Belgium
facility: 205.235.0405 Boehringer Ingelheim Investigational Site
city: Gent
country: Belgium
facility: 205.235.0414 Boehringer Ingelheim Investigational Site
city: Gent
country: Belgium
facility: 205.235.0418 U.Z. Gent
city: Herentals
country: Belgium
facility: 205.235.0417 Boehringer Ingelheim Investigational Site
city: Ieper
country: Belgium
facility: 205.235.0402 Boehringer Ingelheim Investigational Site
city: Kortrijk
country: Belgium
facility: 205.235.0409 Boehringer Ingelheim Investigational Site
city: Leuven
country: Belgium
facility: 205.235.0407 Boehringer Ingelheim Investigational Site
city: Luxembourg
country: Belgium
facility: 205.235.0440 Boehringer Ingelheim Investigational Site
city: Menen
country: Belgium
facility: 205.235.0403 Boehringer Ingelheim Investigational Site
city: Merksem
country: Belgium
facility: 205.235.0406 Boehringer Ingelheim Investigational Site
city: Middelheim
country: Belgium
facility: 205.235.0404 Boehringer Ingelheim Investigational Site
city: Mons
country: Belgium
facility: 205.235.0438 Boehringer Ingelheim Investigational Site
city: Namur
country: Belgium
facility: 205.235.0437 Boehringer Ingelheim Investigational Site
city: Neerpelt
country: Belgium
facility: 205.235.0420 Boehringer Ingelheim Investigational Site
city: Nobressart (ATTERT)
country: Belgium
facility: 205.235.0435 Boehringer Ingelheim Investigational Site
city: Oostende
country: Belgium
facility: 205.235.0423 Boehringer Ingelheim Investigational Site
city: Tournai
country: Belgium
facility: 205.235.0433 Boehringer Ingelheim Investigational Site
city: Turnhout
country: Belgium
facility: 205.235.0412 Boehringer Ingelheim Investigational Site
city: Turnhout
country: Belgium
facility: 205.235.0413 Boehringer Ingelheim Investigational Site
city: Yvoir
country: Belgium
facility: 205.235.0428 Boehringer Ingelheim Investigational Site
city: Florianópolis - SC
country: Brazil
facility: 205.235.510 Servico de Pneumologia
city: Juiz de Fora - MG
country: Brazil
facility: 205.235.508
city: Porto Alegre - RS
country: Brazil
facility: 205.235.501
city: Porto Alegre - RS
country: Brazil
facility: 205.235.503
city: Porto Alegre - RS
country: Brazil
facility: 205.235.506
city: Porto Alegre - RS
country: Brazil
facility: 205.235.507 Depto.de Medicina Interna-Servico de pneumologia
city: Rio de Janeiro - RJ
country: Brazil
facility: 205.235.502
city: Rio de Janeiro - RJ
country: Brazil
facility: 205.235.505 Dep.Medicina Especializada (DEMESP)
city: Salvador - BA
country: Brazil
facility: 205.235.511 Departamento de Pneumologia
city: Santo André - SP
country: Brazil
facility: 205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar
city: São Paulo - SP
country: Brazil
facility: 205.235.512
city: São Paulo - SP
country: Brazil
facility: 205.235.513
city: São Paulo - SP
country: Brazil
facility: 205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina
city: São Paulo - SP
country: Brazil
facility: 205.235.515 Lar Escola São Francisco / Setor de Pneumologia
city: Benesov
country: Czech Republic
facility: 205.235.0712 Boehringer Ingelheim Investigational Site
city: Beroun
country: Czech Republic
facility: 205.235.0711 Boehringer Ingelheim Investigational Site
city: Brno
country: Czech Republic
facility: 205.235.0718 Clinic of Functional Diagnostics and Rehabilitation
city: Brno
country: Czech Republic
facility: 205.235.0725 University Hospital Brno
city: Cesky Tesin
country: Czech Republic
facility: 205.235.0720 Office of Pulmonology and Respiratory Diseases
city: Hradec Kralove
country: Czech Republic
facility: 205.235.0717 Pulmonary Clinic
city: Jablonec nad Nisou
country: Czech Republic
facility: 205.235.0705 Boehringer Ingelheim Investigational Site
city: Jaromer
country: Czech Republic
facility: 205.235.0726 Private Office of Pulmonary Diseases
city: Kromeriz
country: Czech Republic
facility: 205.235.0722 Hospital Kromeriz
city: Kyjov
country: Czech Republic
facility: 205.235.0724 District Hospital Kyjov
city: Lovosice
country: Czech Republic
facility: 205.235.0704 Boehringer Ingelheim Investigational Site
city: Marianske Lazne
country: Czech Republic
facility: 205.235.0702 Boehringer Ingelheim Investigational Site
city: Plzen
country: Czech Republic
facility: 205.235.0701 Boehringer Ingelheim Investigational Site
city: Plzen
country: Czech Republic
facility: 205.235.0703 Boehringer Ingelheim Investigational Site
city: Prague 5
country: Czech Republic
facility: 205.235.0710 Boehringer Ingelheim Investigational Site
city: Praha 4
country: Czech Republic
facility: 205.235.0706 Boehringer Ingelheim Investigational Site
city: Praha 4
country: Czech Republic
facility: 205.235.0709 Boehringer Ingelheim Investigational Site
city: Praha 5 - Nove Butovice
country: Czech Republic
facility: 205.235.0708 Boehringer Ingelheim Investigational Site
city: Praha 5
country: Czech Republic
facility: 205.235.0715 Boehringer Ingelheim Investigational Site
city: Praha 8
country: Czech Republic
facility: 205.235.0707 Boehringer Ingelheim Investigational Site
city: Prerov
country: Czech Republic
facility: 205.235.0723 Office of Pulmonary and Respiratory Diseases
city: Pribor
country: Czech Republic
facility: 205.235.0721 Office of Pulmonary Diseases
city: Strakonice
country: Czech Republic
facility: 205.235.0713 Boehringer Ingelheim Investigational Site
city: Tabor
country: Czech Republic
facility: 205.235.0714 Boehringer Ingelheim Investigational Site
city: Usti nad Orlici
country: Czech Republic
facility: 205.235.0719 Office of Pulmonology and Respiratory Diseases
city: Znojmo
country: Czech Republic
facility: 205.235.0716 Boehringer Ingelheim Investigational Site
city: Aalborg SV
country: Denmark
facility: 205.235.0826 Boehringer Ingelheim Investigational Site
city: Aalborg
country: Denmark
facility: 205.235.0804 Boehringer Ingelheim Investigational Site
city: Aarhus
country: Denmark
facility: 205.235.0803 Boehringer Ingelheim Investigational Site
city: Copenhagen K
country: Denmark
facility: 205.235.0828 Boehringer Ingelheim Investigational Site
city: Copenhagen NV
country: Denmark
facility: 205.235.0802 Boehringer Ingelheim Investigational Site
city: Copenhagen
country: Denmark
facility: 205.235.0831 Boehringer Ingelheim Investigational Site
city: Frederikshavn
country: Denmark
facility: 205.235.0821 Boehringer Ingelheim Investigational Site
city: Frederikssund
country: Denmark
facility: 205.235.0832 Boehringer Ingelheim Investigational Site
city: Fåborg
country: Denmark
facility: 205.235.0807 Boehringer Ingelheim Investigational Site
city: Hellerup
country: Denmark
facility: 205.235.0805 Boehringer Ingelheim Investigational Site
city: Hellerup
country: Denmark
facility: 205.235.0835 Boehringer Ingelheim Investigational Site
city: Helsingor
country: Denmark
facility: 205.235.0816 Boehringer Ingelheim Investigational Site
city: Hillerød
country: Denmark
facility: 205.235.0811 Boehringer Ingelheim Investigational Site
city: Hobro
country: Denmark
facility: 205.235.0834 Boehringer Ingelheim Investigational Site
city: Holbæk
country: Denmark
facility: 205.235.0806 Boehringer Ingelheim Investigational Site
city: Holstebro
country: Denmark
facility: 205.235.0814 Boehringer Ingelheim Investigational Site
city: Hvidovre
country: Denmark
facility: 205.235.0801 Boehringer Ingelheim Investigational Site
city: Kalundborg
country: Denmark
facility: 205.235.0833 Boehringer Ingelheim Investigational Site
city: Kolding
country: Denmark
facility: 205.235.0830 Boehringer Ingelheim Investigational Site
city: Nykobing F.
country: Denmark
facility: 205.235.0819 Boehringer Ingelheim Investigational Site
city: Næstved
country: Denmark
facility: 205.235.0810 Boehringer Ingelheim Investigational Site
city: Odense C
country: Denmark
facility: 205.235.0809 Boehringer Ingelheim Investigational Site
city: Randers
country: Denmark
facility: 205.235.0815 Boehringer Ingelheim Investigational Site
city: Silkeborg
country: Denmark
facility: 205.235.0824 Boehringer Ingelheim Investigational Site
city: Skive
country: Denmark
facility: 205.235.0813 Boehringer Ingelheim Investigational Site
city: Skive
country: Denmark
facility: 205.235.0822 Boehringer Ingelheim Investigational Site
city: Slagelse
country: Denmark
facility: 205.235.0820 Boehringer Ingelheim Investigational Site
city: Svendborg
country: Denmark
facility: 205.235.0808 Boehringer Ingelheim Investigational Site
city: Værløse
country: Denmark
facility: 205.235.0827 Boehringer Ingelheim Investigational Site
city: Helsinki
country: Finland
facility: 205.235.0903 Boehringer Ingelheim Investigational Site
city: Jyväskylä
country: Finland
facility: 205.235.0901 Boehringer Ingelheim Investigational Site
city: Kotka
country: Finland
facility: 205.235.0905 Boehringer Ingelheim Investigational Site
city: Lahti
country: Finland
facility: 205.235.0904 Boehringer Ingelheim Investigational Site
city: Pori
country: Finland
facility: 205.235.0902 Boehringer Ingelheim Investigational Site
city: Albi cedex 9
country: France
facility: 205.235.1004 Clinique Toulouse Lautrec
city: Albi
country: France
facility: 205.235.1007 Cabinet Médical
city: Barbezieux St Hilaire
country: France
facility: 205.235.1015 Centre Hospitalier
city: Bourges
country: France
facility: 205.235.1012 Cabinet Médical
city: Chamalières
country: France
facility: 205.235.1024 Cabinet Médical
city: Chauny cedex
country: France
facility: 205.235.1006 Centre Hospitalier de Chauny
city: Cholet
country: France
facility: 205.235.1005 Polyclinique
city: La Teste
country: France
facility: 205.235.1013 Cabinet Médical
city: Marseille
country: France
facility: 205.235.1020 Cabinet Médical
city: Montauban
country: France
facility: 205.235.1023 Cabinet Médical
city: Nantes
country: France
facility: 205.235.1025 Centre Médical Erdre Saint Augustin
city: Nice
country: France
facility: 205.235.1002 Cabinet médical
city: Paris
country: France
facility: 205.235.1001 Hôpital Bichat
city: Provins
country: France
facility: 205.235.1016 Cabinet Médical
city: Strasbourg
country: France
facility: 205.235.1019 Cabinet Médical
city: Tarbes cedex 9
country: France
facility: 205.235.1009 Centre Hospitalier de Bigorre
city: Toulouse
country: France
facility: 205.235.1021 Clinique Pasteur
city: Berlin
country: Germany
facility: 205.235.1113 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.235.1114 Boehringer Ingelheim Investigational Site
city: Brake
country: Germany
facility: 205.235.1103 Boehringer Ingelheim Investigational Site
city: Braunschweig
country: Germany
facility: 205.235.1105 Boehringer Ingelheim Investigational Site
city: Bruchsal
country: Germany
facility: 205.235.1104 Boehringer Ingelheim Investigational Site
city: Hannover
country: Germany
facility: 205.235.1115 Boehringer Ingelheim Investigational Site
city: Kaufbeuren
country: Germany
facility: 205.235.1109 Boehringer Ingelheim Investigational Site
city: Lörrach
country: Germany
facility: 205.235.1108 Boehringer Ingelheim Investigational Site
city: Lübeck
country: Germany
facility: 205.235.1102 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.235.1106 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.235.1110 Boehringer Ingelheim Investigational Site
city: Ulm
country: Germany
facility: 205.235.1101 Boehringer Ingelheim Investigational Site
city: Weyhe
country: Germany
facility: 205.235.1107 Boehringer Ingelheim Investigational Site
city: Wiesloch
country: Germany
facility: 205.235.1112 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital
city: Athens
country: Greece
facility: 205.235.1203 Boehringer Ingelheim Investigational Site
city: Heraklion
country: Greece
facility: 205.235.1201 Boehringer Ingelheim Investigational Site
city: Kavala
country: Greece
facility: 205.235.1211 Boehringer Ingelheim Investigational Site
city: Larissa
country: Greece
facility: 205.235.1204 Boehringer Ingelheim Investigational Site
city: Patra
country: Greece
facility: 205.235.1209 Boehringer Ingelheim Investigational Site
city: Patra
country: Greece
facility: 205.235.1210 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 205.235.1205 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 205.235.1206 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 205.235.1207 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 205.235.1401 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 205.235.1403 Boehringer Ingelheim Investigational Site
city: Kowloon
country: Hong Kong
facility: 205.235.1402 Boehringer Ingelheim Investigational Site
city: Kowloon
country: Hong Kong
facility: 205.235.1404 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.235.1303 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.235.1308 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.235.1309 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.235.1310 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.235.1311 Boehringer Ingelheim Investigational Site
city: Debrecen
country: Hungary
facility: 205.235.1318 Boehringer Ingelheim Investigational Site
city: Deszk
country: Hungary
facility: 205.235.1314 Boehringer Ingelheim Investigational Site
city: Erd
country: Hungary
facility: 205.235.1306 Boehringer Ingelheim Investigational Site
city: Farkasgyepü
country: Hungary
facility: 205.235.1315 Boehringer Ingelheim Investigational Site
city: Gyula
country: Hungary
facility: 205.235.1320 Boehringer Ingelheim Investigational Site
city: Kiskunhalas
country: Hungary
facility: 205.235.1307 Boehringer Ingelheim Investigational Site
city: Miskolc
country: Hungary
facility: 205.235.1304 Boehringer Ingelheim Investigational Site
city: Mosonmagyarovar
country: Hungary
facility: 205.235.1317 Boehringer Ingelheim Investigational Site
city: Pecs
country: Hungary
facility: 205.235.1301 Boehringer Ingelheim Investigational Site
city: Solymar
country: Hungary
facility: 205.235.1313 Boehringer Ingelheim Investigational Site
city: Sopron
country: Hungary
facility: 205.235.1305 Boehringer Ingelheim Investigational Site
city: Szombathely
country: Hungary
facility: 205.235.1319 Boehringer Ingelheim Investigational Site
city: Tatabanya
country: Hungary
facility: 205.235.1302 Boehringer Ingelheim Investigational Site
city: Törökbalint
country: Hungary
facility: 205.235.1316 Boehringer Ingelheim Investigational Site
city: Veszprem
country: Hungary
facility: 205.235.1312 Boehringer Ingelheim Investigational Site
city: Dublin 15
country: Ireland
facility: 205.235.1505 Boehringer Ingelheim Investigational Site
city: Dublin 4
country: Ireland
facility: 205.235.1503 Boehringer Ingelheim Investigational Site
city: Dublin 9
country: Ireland
facility: 205.235.1501 Boehringer Ingelheim Investigational Site
city: Alessandria
country: Italy
facility: 205.235.1631 A. O. SS. Antonio e Biagio e Arrigo
city: Avellino
country: Italy
facility: 205.235.1613 A. O. S. Giuseppe Moscati
city: Bologna
country: Italy
facility: 205.235.1618 Ospedale Bellaria
city: Busto Arsizio (VA)
country: Italy
facility: 205.235.1649 Ospedale di Circolo di Busto Arsizio
city: Cagliari
country: Italy
facility: 205.235.1635 P. O. Roberto Binaghi
city: Carrara (Massa)
country: Italy
facility: 205.235.1623 A. O. di Carrara
city: CASSANO D'ADDA (Milano)
country: Italy
facility: 205.235.1645 Ospedale Civile "Zappatoni"
city: Chieti
country: Italy
facility: 205.235.1617 Ospedale S. Camillo De Lellis
city: Erice (Trapani)
country: Italy
facility: 205.235.1612 A. O. S. Antonio Abate
city: Ferrara
country: Italy
facility: 205.235.1622 A. O. S. Anna
city: Firenze
country: Italy
facility: 205.235.1646 A. O. di Careggi
city: Firenze
country: Italy
facility: 205.235.1647 A. O. Careggi
city: Genova
country: Italy
facility: 205.235.1615 Ospedale S. Martino
city: Gubbio (Perugia)
country: Italy
facility: 205.235.1603 P. O. di Gubbio
city: Iglesias (Cagliari)
country: Italy
facility: 205.235.1619 A. O. Fratelli Crobu
city: L'Aquila
country: Italy
facility: 205.235.1648 Ospedale "S. Maria di Collemaggio"
city: Macerata
country: Italy
facility: 205.235.1624 Ospedale di Macerata
city: Milano
country: Italy
facility: 205.235.1634 P. O. Luigi Sacco
city: Modica (Ragusa)
country: Italy
facility: 205.235.1639 Ospedale Maggiore
city: Orbassano (Torino)
country: Italy
facility: 205.235.1629 A. O. S. Luigi Gonzaga
city: Perugia
country: Italy
facility: 205.235.1604 P. O. R. Silvestrini
city: Pisa
country: Italy
facility: 205.235.1601 Presidio Ospedaliero di Cisanello
city: Pordenone
country: Italy
facility: 205.235.1643 A. O. Santa Maria degli Angeli
city: Prato
country: Italy
facility: 205.235.1614 Ospedale Misericordia e Dolce
city: Sassari
country: Italy
facility: 205.235.1607 Università degli Studi di Sassari
city: Sassari
country: Italy
facility: 205.235.1608 ASL 1 di Sassari
city: Terni
country: Italy
facility: 205.235.1606 ASL 4 di Terni
city: Torino
country: Italy
facility: 205.235.1632 ASL 4 - Distretto 2
city: Torrette di Ancona (Ancona)
country: Italy
facility: 205.235.1633 A. O. Umberto I
city: Treviso
country: Italy
facility: 205.235.1640 P. O. Cà Foncello
city: Voghera (Pavia)
country: Italy
facility: 205.235.1602 Ospedale di Voghera
city: Bunkyo-ku, Tokyo
country: Japan
facility: 205.235.1706 Juntendo University Hospital
city: Kamogawa, Chiba
country: Japan
facility: 205.235.1705 Kameda Medical Center
city: Komaki, Aichi
country: Japan
facility: 205.235.1713 Komaki City Hospital
city: Kurume, Fukuoka
country: Japan
facility: 205.235.1712 Kurume University Hospital
city: Matsumoto, Nagano
country: Japan
facility: 205.235.1708 Shinshu University
city: Morioka, Iwate
country: Japan
facility: 205.235.1702 Iwate Medical University Hospital
city: Osaka, Osaka
country: Japan
facility: 205.235.1710 Osaka City University Hospital
city: Osakasayama, Osaka
country: Japan
facility: 205.235.1711 Kinki University Hospital
city: Sapporo, Hokkaido
country: Japan
facility: 205.235.1701 Hokkaido University
city: Sendai, Miyagi
country: Japan
facility: 205.235.1703 Tohoku University Hospital
city: Seto, Aichi
country: Japan
facility: 205.235.1709 Tosei General Hospital
city: Yokote, Akita
country: Japan
facility: 205.235.1704 Hiraka General Hospital
city: Kaunas
country: Lithuania
facility: 205.235.1801 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.235.1802 Boehringer Ingelheim Investigational Site
city: Vilnius
country: Lithuania
facility: 205.235.1803 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 205.235.1901 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 205.235.1902 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 205.235.1903 Boehringer Ingelheim Investigational Site
city: Ciudad de Mexico
country: Mexico
facility: 205.235.2005
city: Ciudad de Mexico
country: Mexico
facility: 205.235.2006 Tlalpan 4000, Pabellón 5, EPOC
city: Col. Mitras Centro, Monterrey, N.L.
country: Mexico
facility: 205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.
city: Guadalajara, Jal.
country: Mexico
facility: 205.235.2002
city: Puebla
country: Mexico
facility: 205.235.2009
city: Toluca
country: Mexico
facility: 205.235.2010 Depto. De Ivestigación
city: Zapopan, jalisco
country: Mexico
facility: 205.235.2003
city: Almelo
country: Netherlands
facility: 205.235.2110 Poli Longziekten
city: Amersfoort
country: Netherlands
facility: 205.235.2105 Lokatie De Lichtenberg
city: Delft
country: Netherlands
facility: 205.235.2107 Poli Longziekten
city: Dordrecht
country: Netherlands
facility: 205.235.2106 Lokatie Dordwijk
city: Eindhoven
country: Netherlands
facility: 205.235.2104 Poli longziekten
city: Groningen
country: Netherlands
facility: 205.235.2102 Martini Ziekenhuis Groningen
city: Harderwijk
country: Netherlands
facility: 205.235.2112 Poli Longziekten
city: Heerenveen
country: Netherlands
facility: 205.235.2115 Poli Longziekten
city: Heerlen
country: Netherlands
facility: 205.235.2101 Atrium medisch centrum
city: Hengelo
country: Netherlands
facility: 205.235.2114 Poli Longziekten
city: Leeuwarden
country: Netherlands
facility: 205.235.2108 Poli Longziekten
city: Rotterdam
country: Netherlands
facility: 205.235.2109 Poli Longziekten
city: Sneek
country: Netherlands
facility: 205.235.2111 Antonius Ziekenhuis
city: Auckland
country: New Zealand
facility: 205.235.0211 Boehringer Ingelheim Investigational Site
city: Christchurch, New Zealand
country: New Zealand
facility: 205.235.0212 Boehringer Ingelheim Investigational Site
city: Arendal
country: Norway
facility: 205.235.2202 Boehringer Ingelheim Investigational Site
city: Fredrikstad
country: Norway
facility: 205.235.2201 Boehringer Ingelheim Investigational Site
city: Sandvika
country: Norway
facility: 205.235.2205 Boehringer Ingelheim Investigational Site
city: Straume
country: Norway
facility: 205.235.2204 Boehringer Ingelheim Investigational Site
city: Manila
country: Philippines
facility: 205.235.2301 Philippine General Hospital
city: Manila
country: Philippines
facility: 205.235.2305 University of Santo Tomas Hospital
city: Quezon City
country: Philippines
facility: 205.235.2302 Philippine Heart Center
city: Quezon City
country: Philippines
facility: 205.235.2303 Veterans Memorial Medical Center
city: Quezon City
country: Philippines
facility: 205.235.2304 Lung Center of the Philippines
city: Gdansk
country: Poland
facility: 205.235.2410 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 205.235.2407 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.235.2408 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.235.2405 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.235.2409 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.235.2401 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.235.2402 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.235.2403 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.235.2404 Boehringer Ingelheim Investigational Site
city: Zabrze
country: Poland
facility: 205.235.2406 Boehringer Ingelheim Investigational Site
city: Coimbra
country: Portugal
facility: 205.235.2504 Centro Hospitalar de Coimbra
city: Lisboa
country: Portugal
facility: 205.235.2503 Hospital Pulido Valente
city: Lisboa
country: Portugal
facility: 205.235.2505 Hospital de Santa Marta
city: Porto
country: Portugal
facility: 205.235.2501 Hospital de São João
city: Vila Nova de Gaia
country: Portugal
facility: 205.235.2502 Centro Hospitalar de Vila Nova de Gaia
city: Moscow
country: Russian Federation
facility: 205.235.2601 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.235.2602 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.235.2603 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.235.2605 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.235.2604 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 205.235.1904 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 205.235.1905 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 205.235.1906 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 205.235.2701 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 205.235.2702 Boehringer Ingelheim Investigational Site
city: Martin
country: Slovakia
facility: 205.235.2703 Boehringer Ingelheim Investigational Site
city: Poprad
country: Slovakia
facility: 205.235.2704 Boehringer Ingelheim Investigational Site
city: Topolcany
country: Slovakia
facility: 205.235.2705 Boehringer Ingelheim Investigational Site
city: Golnik
country: Slovenia
facility: 205.235.2801 Boehringer Ingelheim Investigational Site
city: Golnik
country: Slovenia
facility: 205.235.2802 Boehringer Ingelheim Investigational Site
city: Kamnik
country: Slovenia
facility: 205.235.2805 Boehringer Ingelheim Investigational Site
city: Ljubljana
country: Slovenia
facility: 205.235.2803 Boehringer Ingelheim Investigational Site
city: Topolsica
country: Slovenia
facility: 205.235.2804 Boehringer Ingelheim Investigational Site
city: Bloemfontein
country: South Africa
facility: 205.235.2908
city: Cape Town
country: South Africa
facility: 205.235.2910
city: Cape Town
country: South Africa
facility: 205.235.2912
city: Durban
country: South Africa
facility: 205.235.2904
city: Durban
country: South Africa
facility: 205.235.2911
city: George
country: South Africa
facility: 205.235.2902
city: Paarl
country: South Africa
facility: 205.235.2905
city: Pretoria
country: South Africa
facility: 205.235.2901 Boehringer Ingelheim Investigational Site
city: Somerset West
country: South Africa
facility: 205.235.2906
city: Vanderbijlpark
country: South Africa
facility: 205.235.2903
city: Welkom
country: South Africa
facility: 205.235.2909
city: A Coruña
country: Spain
facility: 205.235.3014 Complejo Hospitalario Juan Canalejo
city: Alicante
country: Spain
facility: 205.235.3026 Hospital General Universitario de Alicante
city: Badajoz
country: Spain
facility: 205.235.3011 Complejo Hospitalario Infanta Cristina
city: Badalona (Barcelona)
country: Spain
facility: 205.235.3006 Hospital Germans Trias i Pujol
city: Barakaldo (Bilbao)
country: Spain
facility: 205.235.3022 Hospital de Cruces
city: Barcelona
country: Spain
facility: 205.235.3003 Hospital Clínic i Provincial de Barcelona
city: Barcelona
country: Spain
facility: 205.235.3008 Hospital Vall d'Hebrón
city: Girona
country: Spain
facility: 205.235.3023 Hospital Dr. Josep Trueta
city: Guadalajara
country: Spain
facility: 205.235.3004 Hospital General Universitario de Guadalajara
city: Huesca
country: Spain
facility: 205.235.3005 Hospital General San Jorge de Huesca
city: Jerez de la Frontera
country: Spain
facility: 205.235.3021 Hospital de Jerez de la Frontera
city: Leganés, Madrid
country: Spain
facility: 205.235.3010 Hospital Severo Ochoa
city: Madrid
country: Spain
facility: 205.235.3009 Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: 205.235.3013 Clínica Puerta de Hierro
city: Madrid
country: Spain
facility: 205.235.3017 Hospital Ramón y Cajal
city: Madrid
country: Spain
facility: 205.235.3020 Hospital Universitario La Paz
city: Madrid
country: Spain
facility: 205.235.3028 Hospital Universitario de la Princesa
city: Madrid
country: Spain
facility: 205.235.3031 Hospital Gregorio Marañón
city: Madrid
country: Spain
facility: 205.235.3036 Hospital 12 de Octubre
city: Málaga
country: Spain
facility: 205.235.3033 Hospital General Carlos Haya
city: Palma de Mallorca
country: Spain
facility: 205.235.3027 Complejo Asistencial Son Dureta
city: Pontevedra
country: Spain
facility: 205.235.3024 Hospital de Montecelo
city: Reus (Tarragona)
country: Spain
facility: 205.235.3016 Hospital Universitari de Sant Joan
city: Sabadell (Barcelona)
country: Spain
facility: 205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell
city: Santa Cruz de Tenerife
country: Spain
facility: 205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria
city: Santander
country: Spain
facility: 205.235.3039 Hospital Universitario Marqués de Valdecilla
city: Sevilla
country: Spain
facility: 205.235.3019 Hospital Vírgen de la Macarena
city: Sevilla
country: Spain
facility: 205.235.3035 Hospital Universitario Vírgen del Rocío
city: Terrassa (Barcelona)
country: Spain
facility: 205.235.3001 Hospital Mutua Terrassa
city: Valencia
country: Spain
facility: 205.235.3002 Hospital Clínico Universitario de Valencia
city: Valencia
country: Spain
facility: 205.235.3025 Hospital Universitario Dr. Peset
city: Valencia
country: Spain
facility: 205.235.3032 Hospital Arnau de Vilanova
city: Valencia
country: Spain
facility: 205.235.3034 Hospital La Fe
city: Vigo
country: Spain
facility: 205.235.3018 Complejo Hospitalario Xeral - Cíes
city: Zaragoza
country: Spain
facility: 205.235.3030 Hospital Miguel Servet
city: Zaragoza
country: Spain
facility: 205.235.3038 Hospital Clínico Lozano Blesa
city: Basel
country: Switzerland
facility: 205.235.3202 Boehringer Ingelheim Investigational Site
city: Basel
country: Switzerland
facility: 205.235.3203 Universitätsspital Basel
city: Faltigberg
country: Switzerland
facility: 205.235.3204 Boehringer Ingelheim Investigational Site
city: Lugano
country: Switzerland
facility: 205.235.3205 Boehringer Ingelheim Investigational Site
city: Montana
country: Switzerland
facility: 205.235.3206 Boehringer Ingelheim Investigational Site
city: Winterthur
country: Switzerland
facility: 205.235.3208 Boehringer Ingelheim Investigational Site
city: Zürich
country: Switzerland
facility: 205.235.3201 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 205.235.3301 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 205.235.3302 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 205.235.3303 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 205.235.3402 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 205.235.3403 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 205.235.3404 Boehringer Ingelheim Investigational Site
city: Chiang Mai
country: Thailand
facility: 205.235.3401 Boehringer Ingelheim Investigational Site
city: Khon Kaen
country: Thailand
facility: 205.235.3405 Boehringer Ingelheim Investigational Site
city: Adana
country: Turkey
facility: 205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi
city: Ankara
country: Turkey
facility: 205.235.3506 Hacettepe Tip Fakultesi
city: Ankara
country: Turkey
facility: 205.235.3507 Ankara SSK Diskapi Egitim Hastanesi
city: Ankara
country: Turkey
facility: 205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi
city: Erzurum
country: Turkey
facility: 205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye
city: Eskisehir
country: Turkey
facility: 205.235.3511 Osmangazi Universitesi Tip Fakültesi
city: Istanbul
country: Turkey
facility: 205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi
city: Istanbul
country: Turkey
facility: 205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi
city: Istanbul
country: Turkey
facility: 205.235.3503 Tophanelioglu Cad. No: 13/15
city: Istanbul
country: Turkey
facility: 205.235.3504 Cevizli E5 Karayolu
city: Istanbul
country: Turkey
facility: 205.235.3505 Istanbul Universitesi Tip Fakültesi
city: Izmir
country: Turkey
facility: 205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD
city: Aberdeen
country: United Kingdom
facility: 205.235.3615 Boehringer Ingelheim Investigational Site
city: Chertsey
country: United Kingdom
facility: 205.235.3611 Boehringer Ingelheim Investigational Site
city: Chesterfield
country: United Kingdom
facility: 205.235.3613 Boehringer Ingelheim Investigational Site
city: Cottingham, Hull
country: United Kingdom
facility: 205.235.3608 Boehringer Ingelheim Investigational Site
city: Exeter
country: United Kingdom
facility: 205.235.3605 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 205.235.3602 Boehringer Ingelheim Investigational Site
city: Leeds
country: United Kingdom
facility: 205.235.3610 Boehringer Ingelheim Investigational Site
city: Leicester
country: United Kingdom
facility: 205.235.3607 Boehringer Ingelheim Investigational Site
city: Middleton
country: United Kingdom
facility: 205.235.3604 Boehringer Ingelheim Investigational Site
city: Nottingham
country: United Kingdom
facility: 205.235.3612 Boehringer Ingelheim Investigational Site
city: Paisley
country: United Kingdom
facility: 205.235.3616 Boehringer Ingelheim Investigational Site
city: Penarth
country: United Kingdom
facility: 205.235.3614 Boehringer Ingelheim Investigational Site
city: Plymouth
country: United Kingdom
facility: 205.235.3603 Boehringer Ingelheim Investigational Site
city: Sheffield
country: United Kingdom
facility: 205.235.3609 Boehringer Ingelheim Investigational Site
city: Solihull, Birmingham
country: United Kingdom
facility: 205.235.3601 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Gronke L, Voss F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 9;21(1):177. doi: 10.1186/s12931-020-01431-y.
citation: Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT(R) trial. Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.
citation: Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT(R) trial. Respir Res. 2016 May 4;17(1):48. doi: 10.1186/s12931-016-0361-4.
citation: Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.
citation: Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014 Aug 31;15(1):102. doi: 10.1186/s12931-014-0102-5.
citation: Janssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, Decramer M. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT(R)). Respir Med. 2013 Sep;107(9):1409-16. doi: 10.1016/j.rmed.2013.04.015. Epub 2013 May 25.
citation: Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 >/= 60% participating in the UPLIFT(R) trial. COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.
citation: Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res. 2011 Sep 28;12(1):129. doi: 10.1186/1465-9921-12-129.
citation: Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.
citation: Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.
citation: Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.
citation: Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.